Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead

Nektar Therapeutics' rezpegaldesleukin showed strong phase 2b results in eczema but the company remains pre-commercial with ongoing net losses and substantial downside risk if the asset fails in late-stage trials. By contrast, Madrigal Pharmaceuticals secured U.S. approval for Rezdiffra in 2024 and reported $287.3 million in net sales in Q3, with the drug on track for blockbuster status next year despite being on accelerated approval pending confirmatory trials. The piece recommends Madrigal as the less risky investment today while flagging regulator dependence and ongoing trial risk for both companies.

Analysis

Market structure: Madrigal (MDGL) is the nearest-term beneficiary — $287.3M Q3 sales imply a ~ $1.15B annualized run‑rate and positions Rezdiffra as a >$1B blockbuster candidate in MASH, tightening pricing power vs. future entrants. Nektar (NKTR) is a binary-risk loser in the short term: strong phase 2b lifts optionality but a phase 3 failure could erase >70% equity value (aTyr analog). Lift to MDGL tightens supply-demand for an underserved MASH market (demand >> current supply), increasing sector M&A interest and reducing short-term price elasticity.

Risk assessment: Tail risks include NKTR phase‑3 failure (low probability, high impact) and MDGL losing accelerated approval if confirmatory trials fail (mid probability with high downside). Immediate (days) risks are sentiment/earnings; weeks–months hinge on enrollment and payer coverage updates; long term (12–36 months) depends on confirmatory outcomes and real-world safety. Hidden dependencies: payer reimbursement thresholds, manufacturing scale, and prescription trend persistence (prescription retention >70% at 6 months is a positive KPI).

Trade implications: Favor a size‑limited overweight in MDGL and a small, asymmetric exposure to NKTR upside while protecting capital. Practicals: establish a 1–3% long MDGL position (trim if +25–40% within 6–12 months), sell 3–6 month covered calls 10–25% OTM to monetize uptake, and allocate 0.5–1% to NKTR 12–18 month OTM calls (asymmetric upside) or a 1–2% short for risk-tolerant accounts. Rebalance after quarterly sales (next 30–60 days) and any phase‑3 protocol announcements.

Contrarian angles: Consensus underprices persistence of MDGL uptake and overprices NKTR binary risk — MDGL could sustain >$250M quarterly if formulary access holds, making downside limited relative to NKTR. Conversely, NKTR’s phase‑2 signal could be underappreciated: a successful phase‑3 would re-rate shares >2–3x, so small option exposure is preferred to outright omission. Watch for unintended consequences: payer volume limits for Rezdiffra or rapid competitive entries that could compress pricing within 12–24 months.

Key Decisions for Investors

• Establish a 1–3% portfolio long position in MDGL over the next 2–6 weeks, target hold 6–12 months; trim into strength at +25–40% or if quarterly net sales drop below $200M (QoQ).
• Implement covered-call income on MDGL: sell 3–6 month calls ~10–25% OTM on half the position to harvest premium while retaining upside through next two quarters of uptake data.
• Allocate 0.5–1% to NKTR 12–18 month OTM calls (25–50% OTM) for asymmetric upside; OR, for risk-tolerant portfolios, a 1–2% short NKTR equity position with a strict 20–25% stop-loss to hedge binary downside.
• Execute a pair trade for relative value: long MDGL 2% vs short NKTR 1–2% notional to express safety-over-volatility; reprice after MDGL quarterly sales (next 30–60 days) and any NKTR phase‑3 design announcement.
• Monitor three binary KPIs in the next 60–180 days before scaling positions: MDGL quarterly net sales (threshold >$250M/quarter confirms momentum), NKTR phase‑3 start/enrollment milestones, and any FDA correspondence on MDGL confirmatory trial timelines.